EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Opus Genetics's enterprise value is $13.30 Mil.
Opus Genetics's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was $13.65 Mil. Therefore, Opus Genetics's EV-to-Revenue for today is 0.97.
The historical rank and industry rank for Opus Genetics's EV-to-Revenue or its related term are showing as below:
IRD'
s EV-to-Revenue Range Over the Past 10 Years
Min: -1.32 Med: 0.99 Max: 483.02
Current: 0.97
During the past 6 years, the highest EV-to-Revenue of Opus Genetics was 483.02. The lowest was -1.32. And the median was 0.99.
IRD's EV-to-Revenue is ranked better than 86.33% of 995
companies
in the Biotechnology industry
Industry Median: 7.63
vs IRD: 0.97
As of today (2025-06-26), Opus Genetics's stock price is $0.9702.
Opus Genetics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 was $0.46. Therefore, Opus Genetics's PS Ratio for today is 2.10.
Opus Genetics EV-to-Revenue Historical Data
The historical data trend for Opus Genetics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Opus Genetics's EV-to-Revenue
For the Biotechnology subindustry, Opus Genetics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Opus Genetics's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Opus Genetics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Opus Genetics's EV-to-Revenue falls into.
Opus Genetics's current Enterprise Value is $13.30 Mil.
Opus Genetics's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $13.65 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Opus Genetics's share price for today is $0.9702.
Opus Genetics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.46.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Opus Genetics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Opus Genetics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
IRD has been successfully added to your 